Cargando…

Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)

Since its first description in November 2021, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) has emerged as the dominant strain in the COVID-19 pandemic. To date, it remains unclear if boosted vaccination protects against transmission. Using data from the largest German Public Health Departme...

Descripción completa

Detalles Bibliográficos
Autores principales: Grüne, Barbara, Grüne, Jakob, Kossow, Annelene, Joisten, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322361/
https://www.ncbi.nlm.nih.gov/pubmed/35891167
http://dx.doi.org/10.3390/vaccines10071003
_version_ 1784756284303605760
author Grüne, Barbara
Grüne, Jakob
Kossow, Annelene
Joisten, Christine
author_facet Grüne, Barbara
Grüne, Jakob
Kossow, Annelene
Joisten, Christine
author_sort Grüne, Barbara
collection PubMed
description Since its first description in November 2021, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) has emerged as the dominant strain in the COVID-19 pandemic. To date, it remains unclear if boosted vaccination protects against transmission. Using data from the largest German Public Health Department, Cologne, we analyzed breakthrough infections in booster-vaccinated infected persons (IP; booster-vaccinated group (BVG); n = 202) and fully vaccinated, not boosted SARS-COV2-positive patients (>3 month after receiving the second dose; unboosted, fully vaccinated group (FVG); n = 202) to close contacts compared to an age- and sex-matched unvaccinated control group (UCG; n = 202). On average, IPs had 0.42 ± 0.52 infected contacts in relation to the total number of contacts in the BVG vs. 0.57 ± 0.44 in the FVG vs. 0.56 ± 0.43 in the UVG (p = 0.054). In the median test, pairwise comparison revealed a significant difference between the BVG and both other groups; no difference was found between the fully vaccinated and the unvaccinated control group. Now, these findings must be verified in larger samples, considering the role of Omicron subvariants and the vaccination status of the contact person. However, the importance of the booster vaccination in breaking possible chains of infection in the immune escape variant Omicron is obvious.
format Online
Article
Text
id pubmed-9322361
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93223612022-07-27 Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) Grüne, Barbara Grüne, Jakob Kossow, Annelene Joisten, Christine Vaccines (Basel) Communication Since its first description in November 2021, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) has emerged as the dominant strain in the COVID-19 pandemic. To date, it remains unclear if boosted vaccination protects against transmission. Using data from the largest German Public Health Department, Cologne, we analyzed breakthrough infections in booster-vaccinated infected persons (IP; booster-vaccinated group (BVG); n = 202) and fully vaccinated, not boosted SARS-COV2-positive patients (>3 month after receiving the second dose; unboosted, fully vaccinated group (FVG); n = 202) to close contacts compared to an age- and sex-matched unvaccinated control group (UCG; n = 202). On average, IPs had 0.42 ± 0.52 infected contacts in relation to the total number of contacts in the BVG vs. 0.57 ± 0.44 in the FVG vs. 0.56 ± 0.43 in the UVG (p = 0.054). In the median test, pairwise comparison revealed a significant difference between the BVG and both other groups; no difference was found between the fully vaccinated and the unvaccinated control group. Now, these findings must be verified in larger samples, considering the role of Omicron subvariants and the vaccination status of the contact person. However, the importance of the booster vaccination in breaking possible chains of infection in the immune escape variant Omicron is obvious. MDPI 2022-06-23 /pmc/articles/PMC9322361/ /pubmed/35891167 http://dx.doi.org/10.3390/vaccines10071003 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Grüne, Barbara
Grüne, Jakob
Kossow, Annelene
Joisten, Christine
Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
title Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
title_full Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
title_fullStr Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
title_full_unstemmed Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
title_short Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
title_sort vaccination and transmission risk during the outbreak of b.1.1.529 (omicron)
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322361/
https://www.ncbi.nlm.nih.gov/pubmed/35891167
http://dx.doi.org/10.3390/vaccines10071003
work_keys_str_mv AT grunebarbara vaccinationandtransmissionriskduringtheoutbreakofb11529omicron
AT grunejakob vaccinationandtransmissionriskduringtheoutbreakofb11529omicron
AT kossowannelene vaccinationandtransmissionriskduringtheoutbreakofb11529omicron
AT joistenchristine vaccinationandtransmissionriskduringtheoutbreakofb11529omicron